Clare Houghton provides a case study on how to manage income tax with a Knowledge-Intensive (KI) EIS fund. Our KI EIS Fund can be used to reduce income tax paid in 2022/2023, and due to our rapid deployment, the tax reliefs will be available during 2024. This is technical tax planning webinar hosted by Clare,
MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, has closed a £7m Series A financing round led by Mercia Ventures. Existing investor Calculus Capital also participated in the round, along with angel investors. The investment marks a pivotal change for MIP Discovery
Invizius Limited, a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce that the first two patients have been treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with lead product, H-Guard® Priming Solution, in the Company’s first-in-human Phase 1 clinical study. The UK
Join Russell Fryer as he demonstrates how to manage capital gains tax with a Knowledge-Intensive (KI) EIS fund. This is technical tax planning webinar, which may be very relevant to your clients in the run up to the tax year end. *𝗣𝗹𝗲𝗮𝘀𝗲 𝗿𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗿𝗶𝘀𝗸 𝘄𝗮𝗿𝗻𝗶𝗻𝗴𝘀* Visit Mercia’s EIS area
Mercia Ventures, one of the UK’s most active investors, has expanded its platform to further support the expansion of its portfolio companies and help them gain entry into the competitive US marketplace. The service has been bolstered by the addition of two new Growth Partners, both of whom are based in the US and have years
Join Paul Mattick, as he discusses why many people prefer the Knowledge-Intensive (KI) EIS fund. The differences between an “unapproved” EIS fund and a “KI” EIS are small but are important, and provide interesting tax planning opportunities. *𝗣𝗹𝗲𝗮𝘀𝗲 𝗿𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗿𝗶𝘀𝗸 𝘄𝗮𝗿𝗻𝗶𝗻𝗴𝘀* Visit Mercia’s EIS area
The adage “a team is only as strong as its weakest link” resonates profoundly within today’s complex supply chains. The rising frequency of cyberattacks in supply chains – a trend highlighted by Gartner’s prediction that by 2025, nearly half of all organiszations will experience attacks through their software supply chains – underscores this vulnerability. A
We feel privileged to have backed the Founders of over 100 software businesses at Seed to Series A over the years. Despite 2023 being one of the gloomiest years in venture in recent memory, we continued to be active, with new investments into Social Value Portal, Risk Ledger, Centuro Global, HowNow, Kuano, Envoke-Demos, Huler, FourJaw
Last year, Mercia Ventures spearheaded a £2 million investment into ImmuONE, the spin-out developing groundbreaking 3D human lung models that reduce reliance on animal testing. Before a new drug, chemical or product is launched, assessing safety for humans is crucial. Historically, this often meant testing on animals. Not only does this pose ethical concerns, but
Cell and gene based therapies are the next frontier in medicine. Unlike other therapies they have the potential to cure diseases as opposed to merely treating the disease, as is the case with more traditional treatment modalities. It feels like they almost belong in a sci-fi movie; genetically engineering a patient’s own cells or replacing